BioMarin Pharmaceutical Inc. (BMRN)

Market Cap	15.61B
Revenue (ttm)	2.47B
Net Income (ttm)	205.46M
Shares Out	189.88M
EPS (ttm)	1.06
PE Ratio	77.57
Forward PE	44.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,063,939
Open	82.08
Previous Close	82.13
Day's Range	81.55 - 82.44
52-Week Range	73.68 - 99.56
Beta	0.31
Analysts	Buy
Price Target	105.45 (+28.25%)
Earnings Date	Jul 29, 2024

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 1999
• Employees: 3,401
• Stock Exchange: NASDAQ
• Ticker Symbol: BMRN

Financial Performance

In 2023, BMRN's revenue was $2.42 billion, an increase of 15.42% compared to the previous year's $2.10 billion. Earnings were $167.65 million, an increase of 18.43%.

Analyst Forecast

According to 21 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $105.45, which is an increase of 28.25% from the latest price.

Price Target

$105.45

(28.25% upside)

Analyst Consensus: Buy